Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss

Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss

Bioton S.A. - headquartered at ul. Starościńska 5 in Warsaw (postcode 02-516, Mazowieckie voivodeship), registered in the KRS under number 0000214072 - has published its consolidated 2025 report. Group revenue came to PLN 235.9 m (+13.5% YoY versus PLN 207.8 m in 2024); EBITDA rose 76% to PLN 53.82 m (margin 18.72%, vs PLN 30.6 m a year earlier). Despite that, at the net level the Group remains in the red: the estimated 2025 net loss is around PLN -16.4 m, similar to the PLN 15.6 m loss reported in 2024 (and in clear contrast to the PLN 2.3 m profit recorded in 2023).

Positive operating signals include the contract for contract manufacturing of the insulin analogue Glargine (February 2025, entry to the Polish market after reimbursement in mid-2025), the inclusion of human insulin and analogues on the EU and Polish Ministry of Health critical-medicines lists since 2024, and the lowest bank debt in the company's history at PLN 29.6 m. Q1 2025 showed revenue jumping 75% YoY (to PLN 65.6 m), but at the same time gross margin fell to 20.4% - signalling a structural divergence between foreign expansion (lower-margin emerging markets) and the Polish reimbursement market.

Bioton

MACIERZYSZ · KRS 0000214072 · SPÓŁKA AKCYJNA

Revenue

282.5 M PLN

Starościńska 5: Launders' 2-member board, Yifan Pharmaceutical control through Singapore vehicles

The address ul. Starościńska 5, 02-516 Warsaw places Bioton's seat in the Mokotów business strip of the capital. The company has operated in its current corporate form (Bioton S.A., KRS 0000214072) since 2 August 2004 and has been listed on the Warsaw Stock Exchange since 2005. It belongs to the sWIG80.

Governance: a two-member management board - CEO Jeremy Launders plus one board member. The shareholder base is international and fragmented: the largest controlling shareholder remains China's Yifan Pharmaceutical, which holds 31.65% of capital indirectly through the Singapore SPVs Dongren Singapore (19.79%) and Perfect Trend Ventures (11.86%) - as of 30 April 2026. Other significant shareholders: Basolma Holding 7.16%, Mirosław Czarnik with the ABM Family Foundation 6.49%, Altus/AIS Investment 2 6.00%, Cu Wenjun (via Uniapek) 5.00%. Free float is around 48.7%.

Under Polish PKD codes the principal activity is 21.20.Z (manufacture of pharmaceutical preparations). Bioton is Poland's only manufacturer of biosynthetic human insulin - the flagship product is Gensulin (with the SciLin and Genrex brands on export markets). The company has a registered electronic-delivery address (AE:PL-71202-20543-DWAJJ-27), the e-mail bioinfo@bioton.com and the website bioton.com.

Polish pharma-and-biotech sector on the WSE: Bioton as the only Polish human-insulin producer

The Polish biotech-pharma sector listed on the Warsaw exchange has clear segmentation in 2026:

• Bioton - biosynthetic insulin production, the only such Polish player, post-revenue but with a negative net result.
• Mabion (Konstantynów Łódzki, mWIG40) - contract biotech with the Novavax CDMO contract - post-revenue, lower risk than Bioton.
• Bioceltix (Wrocław) - pre-commercial veterinary biotech (canine/equine cell therapies), in final EMA dialogue for BCX-CM-J.
• Ryvu Therapeutics (Kraków, mWIG40) - pre-commercial oncology biotech, RVU120 in Phase II.
• Selvita - contract CRO, post-revenue, low risk profile.
• Captor Therapeutics, Celon Pharma, Medicalgorithmics - smaller players.

Three structural features of the Bioton model that explain the divergence between EBITDA improvement and the persistent net loss:

• Global expansion as a revenue engine but a margin pressure - sales on emerging markets (Malaysia ~PLN 100 m a year, Brazil, South Africa, India) generate volume, but at lower prices and higher logistics costs. The Polish market (insulin reimbursement by MoH) is margin-better but volume-limited - hence Q1 2025 gross margin fell to 20.4%.
• Yifan Pharmaceutical control as a strategic partner and a risk - the controlling Chinese owner gives Bioton access to Asian insulin-API supply chains and expansion financing, but can also push strategic decisions in the parent group's interest (e.g. product priorities, transfer pricing, production location). It is a two-way dependency whose structural stability depends on Yifan's multi-year policy.
• Insulin as an EU critical medicine = political support for the Polish producer - listing human insulin and analogues on the EU and Polish critical-medicines list in 2024 gives Bioton long-term regulatory protection against full import (the EU wants internal production in critical cases). It is a structural advantage versus competitors Sanofi (Lantus), Eli Lilly (Humalog) and Novo Nordisk (Tresiba).

Implication for the investment profile: EBITDA improvement, but no dividend until the company breaks even

The interpretation is speculative - the conclusions below are scenarios, not certainties:

“We continue cost discipline and product-portfolio expansion, with particular focus on emerging markets with insulin shortages.”

Three possible consequences of the 2025 results for Bioton's investment profile in 2026:

• The 76% EBITDA improvement is a real operating signal but insufficient for a dividend - EBITDA growth from PLN 30.6 m to PLN 53.8 m demonstrates that expansion to emerging markets is actually translating into operating leverage. If the trend holds in 2026 (e.g. EBITDA grows another 30-40%), net profit may finally turn positive. Only then does a dividend discussion make sense - accumulated losses from prior years exclude any payout out of 2025.
• Q1 2025 = a trend signal, but the margin gap warrants caution - Q1 revenue +75% YoY at a falling gross margin (20.4%) signals that volume momentum has not yet translated into durable profitability. Investors should watch whether the rest of 2026 sustains revenue growth alongside a stable or rising margin - that would be the first real signal of structural improvement.
• The lowest-ever bank debt (PLN 29.6 m) provides financial space - combined with cost discipline from Jeremy Launders, this signals that the company is consciously reducing financing cost in the face of a persistent net loss. It buys room to extend the recovery cycle should margins decline further.

Main company-specific risks across the 2026–2027 cycle:

• Persistent net loss - accumulated losses exclude dividends; would require profit generation across 2-3 consecutive years before any payout.
• Falling gross margin (Q1 2025: 20.4%) - a signal of the structural divergence between expansion and profitability.
• Sanofi/Lilly/Novo Nordisk competition in insulin analogues - global pharma giants have significantly larger R&D budgets and production capacity.
• Yifan Pharmaceutical control (31.65% indirectly) - parent-group decisions may steer the strategic direction independently of Polish minority-shareholder interests.
• Political risk of EU-China tariffs - as a company controlled by Chinese capital, Bioton is potentially exposed to changes in EU policy toward Chinese investments in strategic sectors (a critical medicine).

What you'll find in the Bioton S.A. profile

The Bioton S.A. profile in our database carries the full picture of the company: composition of the two-member management board (with CEO Jeremy Launders), the KRS registration history from 2 August 2004, the registered address at ul. Starościńska 5 in Warsaw, e-delivery status (AE:PL-71202-20543-DWAJJ-27), the website bioton.com, the e-mail bioinfo@bioton.com, and the assigned PKD code 21.20.Z (manufacture of pharmaceuticals). The profile is also available in English - important for international biotech-pharma fund investors, since Bioton is the only Polish manufacturer of biosynthetic human insulin, controlled by China's Yifan Pharmaceutical and with active emerging-market expansion.

This material is informational and does not constitute investment advice.

Data: Polish KRS Court Register (KRS 0000214072); Bioton S.A. - consolidated annual report SRR/2025 (29 April 2026); Bankier ESPI - Bioton SRR/2025; Stockwatch - Bioton financial indicators and shareholder structure; Parkiet - analysis of Bioton 2024 results and Q1 2025; Strefa Inwestorów - Bioton shareholder structure (30 April 2026); PKD 21.20.Z classification (manufacture of pharmaceutical preparations); company history - incorporated 2 August 2004, WSE IPO 2005, as of 2026-05-02.